Welcome to our dedicated page for KYNTRA BIO SEC filings (Ticker: KYNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyntra Bio filings document the company's public-company governance, financial reporting, clinical-development updates, and Nasdaq listing matters. Recent 8-K reports cover results of operations and financial condition, including business updates tied to FG-3246, roxadustat, and the FG-3180 biomarker program.
The filing record also includes definitive proxy statements that disclose governance matters, executive compensation, equity awards, and shareholder voting information. Additional 8-K disclosure addresses Nasdaq continued-listing compliance, reflecting the company's capital-market and reporting obligations as a Nasdaq-listed biopharmaceutical issuer.
Kyntra Bio, Inc. reported results from its 2026 annual stockholder meeting held on June 12, 2026. Stockholders elected Class III director Michael Kauffman, M.D., Ph.D., to serve until the 2029 annual meeting, with 1,239,169 votes for, no votes against, 51,081 withheld, and 1,444,428 broker non-votes.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 1,242,005 votes for, 23,606 against, 24,639 abstentions, and 1,444,428 broker non-votes. In addition, they ratified the Audit Committee’s selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 2,712,825 votes for, 14,392 against, and 7,461 abstentions.
KYNTRA BIO, INC. CEO Thane Wettig reported routine share updates in a Form 4. The filing shows 198 shares of common stock were disposed of to cover a tax obligation at $6.71 per share when restricted stock units vested, a non‑market transaction. After this withholding, he directly holds 27,005 common shares and has an additional 40 shares reported as indirectly owned through his spouse.
KYNTRA BIO, INC. Chief Financial Officer David DeLucia reported a routine tax-related share disposition tied to equity compensation. On the reported date, 52 shares of common stock were withheld by the company at a value of $6.71 per share to satisfy a tax obligation that arose when restricted stock units vested. Following this withholding, DeLucia holds 4,377 shares of KYNTRA BIO common stock directly.
Kyntra Bio, Inc. received $4.0 million from AstraZeneca Treasury Limited on June 2, 2026. This payment represents the second and final holdback under their February 20, 2025 share purchase agreement covering the sale of Kyntra’s China operations.
The China business was sold to AstraZeneca on August 29, 2025 for total consideration of approximately $220 million, including $85 million in enterprise value and about $135 million in net cash held in China. Kyntra had previously collected $210 million at closing and a first holdback of $6.0 million plus an additional $0.4 million after final net cash adjustments. With this latest $4.0 million payment, the company has now received all amounts owed under the agreement.
KYNTRA BIO, INC. CEO and director Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, increasing his direct holdings to 27,203 shares. A separate line shows 40 shares of common stock held indirectly through his spouse.
KYNTRA BIO, INC. CEO Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, bringing his direct holdings to 27,203 shares. He also reports indirect ownership of 40 shares held by his spouse.
KYNTRA BIO, INC. filing shows Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 400,000 shares of common stock, representing 9.88% of the class.
The filing states Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares; Mr. Boyd is the managing member of Armistice Capital. Signatures are dated May 15, 2026.
Kyntra Bio, Inc. reported first-quarter 2026 revenue of $3.7 million, up from $2.7 million a year earlier, driven mainly by $3.5 million of drug product sales of roxadustat API and bulk product to Astellas. Operating costs and expenses were $17.6 million, roughly flat year over year.
The company posted a loss from continuing operations of $15.1 million, or $3.74 per share, compared with a loss of $16.8 million, or $4.15 per share, in 2025. Net loss was $15.2 million versus net income of $4.6 million last year, when results included $21.4 million of income from discontinued China operations. Cash, cash equivalents, short- and long-term investments, and accounts receivable totaled about $100.3 million, and management believes this will fund operations for at least 12 months. Kyntra continues to develop FG-3246 for metastatic castration-resistant prostate cancer and advance roxadustat into a planned Phase 3 trial for anemia in lower-risk MDS.
Kyntra Bio reported first quarter 2026 results, showing total revenue from continuing operations of $3.7 million, up from $2.7 million a year earlier, driven mainly by higher drug product revenue. Net loss from continuing operations narrowed to $15.1 million, or $3.74 per share, compared with a $16.8 million loss, or $4.15 per share, in 2025.
The company ended March 31, 2026 with $100.3 million in cash, cash equivalents, investments, and accounts receivable and expects this to fund its operating plans into 2028. Kyntra highlighted steady progress in its pipeline, including an actively enrolling Phase 2 trial of FG-3246 in metastatic castration-resistant prostate cancer with an interim analysis planned for the fourth quarter of 2026, and finalization of a pivotal Phase 3 roxadustat protocol in lower-risk myelodysplastic syndromes ahead of a targeted trial start in the second half of 2026.